Clinical trials: Asthma/ COPD
Asthma, Chronic Obstructive Pulmonary Disease
Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease
To investigate how a switch from fixed combination treatment (ICS and LABA) to other treatments influence asthma or COPD treatment failure
- Trial name
- NCT01369810
- Where
- Sweden
- Volunteers
- 20,000 people
- Sponsor
- AstraZeneca
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
- Trial name
- NCT07116889
- Testing
- GB-0895 (SC)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Generate Biomedicines
Asthma, Chronic Obstructive Pulmonary Disease
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, COPD
- Trial name
- NCT00583986
- Testing
- Levalbuterol HFA MDI with top mounted actuation indicator
- Where
- 26 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two…
- Trial name
- NCT02648438
- Testing
- AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cough, Asthma
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
- Conditions
- Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
- Trial name
- C-mo_01 (NCT05989698)
- Testing
- C-mo System
- Where
- 8 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Cough Monitoring Medical Solutions
Asthma, Bronchospasm
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered…
- Conditions
- Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01189396
- Testing
- A006, Proventil-HFA
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Asthma, Chronic Obstructive Pulmonary Disease
Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI)…
- Trial name
- NCT02968914
- Testing
- Benralizumab
- Where
- 2 sites in Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Asthma
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT02059434
- Testing
- LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society
This study is a multicentered and non-interventional prospective cohort study. Study centers shall be the institutions where the examinations, adopted in the ACO diagnostic criteria9) from The Japanese Respiratory Society, are…
- Trial name
- ACO-Registry (NCT03577795)
- Where
- Japan
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc
Asthma, Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
This study has two parts. The main purpose of Part 1 of this study will be to examine how safe and effective two doses of SelK2 is on participants with mild asthma.
- Trial name
- NCT04540042
- Testing
- SelK2 (Part 1), SelK2 (Part 2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Tetherex Pharmaceuticals Corporation
Asthma, COPD
Prospective evAluatIon foR Inhalation Devices Study
ASTHMA: Asthma is a chronic inflammatory disorder of the airways in which many different types of cells, and various cellular components.
- Trial name
- PAIR (NCT01800994)
- Where
- 6 sites in Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma, COPD
A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)
This study will compare the patient handling of Flutiform® pMDI (pressurised metered dose inhaler) and a breath activated device (BAI).
- Trial name
- NCT01739387
- Testing
- Flutiform® pMDI and Breath Actuated Inhaler (BAI)
- Where
- 2 sites in United Kingdom
- Volunteers
- 332 people
- Sponsor
- Mundipharma Research Limited
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00452400
- Testing
- BI 1744CL
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 409 people
- Sponsor
- Boehringer Ingelheim